Skip to main content
SpringerLink
Log in

Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)

Stand Januar 2018

Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy

Situation January 2018

  • Leitlinien, Stellungnahmen und Empfehlungen
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

An Erratum to this article was published on 08 May 2018

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Change history

  • 08 May 2018

    Erratum zu:

    Ophthalmologe 2018

    DOI https://doi.org/10.1007/s00347-018-0680-6

    Sehr geehrter Leser,

    sehr geehrte Leserin,

    die Onlineversion dieses Artikels wurde geändert: Leider wurde der Beitrag mit fehlerhafter Abb. 1 veröffentlicht, auch hat sich im Abschnitt Kernaussagen/Therapie/Lasertherapie ein …

Literatur

  1. Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101

    PubMed  PubMed Central  Google Scholar 

  2. Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79–82

    Article  CAS  PubMed  Google Scholar 

  3. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–792.e2

    Article  CAS  PubMed  Google Scholar 

  4. Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237

    Article  CAS  PubMed  Google Scholar 

  5. Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899–906

    Article  PubMed  Google Scholar 

  6. Bousquet E, Beydoun T, Rothschild P‑R, Bergin C, Zhao M, Batista R, Brandely M‑L, Couraud B, Farman N, Gaudric A et al (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505–2515

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A (2017) Optical coherence tomography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina. https://doi.org/10.1097/IAE.0000000000001580

    Google Scholar 

  8. Bujarborua D (2001) Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 79:417–421

    Article  CAS  PubMed  Google Scholar 

  9. Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK (2005) Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 25:422–429

    Article  PubMed  Google Scholar 

  10. Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351

    Article  PubMed  Google Scholar 

  11. Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2010) Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 4:899–903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chan W‑M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chan W‑M, Lai TYY, Lai RYK, Liu DTL, Lam DSC (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765

    Article  PubMed  Google Scholar 

  14. Cheng C‑K, Chang C‑K, Peng C‑H (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37:325–333

    Article  CAS  PubMed  Google Scholar 

  15. Chong C‑F, Yang D, Pham TQ, Liu H (2012) A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. https://doi.org/10.1136/bcr-2012-006970

    PubMed  PubMed Central  Google Scholar 

  16. Chuang EL, Sharp DM, Fitzke FW, Kemp CM, Holden AL, Bird AC (1987) Retinal dysfunction in central serous retinopathy. Eye (Lond) 1(Pt 1):120–125

    Article  Google Scholar 

  17. Chung Y‑R, Seo EJ, Lew HM, Lee KH (2013) Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye 27:1339–1346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82. https://doi.org/10.1016/j.preteyeres.2015.05.003

    Article  CAS  PubMed  Google Scholar 

  19. Daruich A, Matet A, Marchionno L, De Azevedo J‑D, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37(10):1905. https://doi.org/10.1097/IAE.0000000000001443

    Article  PubMed  PubMed Central  Google Scholar 

  20. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36:718–729

    CAS  PubMed  Google Scholar 

  21. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR (2003) Central serous chorioretinopathy in African Americans. J Natl Med Assoc 95:553–559

    PubMed  PubMed Central  Google Scholar 

  22. Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J (2006) Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 244(12):1638–1645

    Article  CAS  PubMed  Google Scholar 

  23. Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274

    Article  PubMed  Google Scholar 

  26. Gäckle HC, Lang GE, Freissler KA, Lang GK (1998) Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 95(8):529–533

    Article  PubMed  Google Scholar 

  27. de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650–656

    PubMed  Google Scholar 

  28. Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747

    Article  CAS  PubMed  Google Scholar 

  29. Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Haimovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703

    Article  PubMed  Google Scholar 

  31. Heinrich MR (1974) Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr 74:681–683

    CAS  PubMed  Google Scholar 

  32. Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897

    Article  PubMed  Google Scholar 

  33. Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S (2003) Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23:1–7 (quiz 137-8)

    Article  PubMed  Google Scholar 

  34. Jain AK, Kaines A, Schwartz S (2010) Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 248:1037–1039

    Article  PubMed  Google Scholar 

  35. de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570

    Article  PubMed  Google Scholar 

  36. Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK (2007) Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 245:460–463

    Article  PubMed  Google Scholar 

  37. Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A (2003) Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 87:709–712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115:169–173

    Article  PubMed  Google Scholar 

  39. Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J (2011) Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 95:83–88

    Article  CAS  PubMed  Google Scholar 

  40. Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG, MINERVA study group (2017) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. https://doi.org/10.1097/IAE.0000000000001744

    Google Scholar 

  41. Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015) Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 200:25–29

    Article  PubMed  Google Scholar 

  42. Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34:87–97

    Article  PubMed  Google Scholar 

  43. Leaver P, Williams C (1979) Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 63:674–677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lee H, Lee J, Chung H, Kim HC (2016) Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 36:1372–1380

    Article  CAS  PubMed  Google Scholar 

  45. Lim JI, Spee C, Hinton DR (2010) A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 30:1472–1478

    Article  PubMed  PubMed Central  Google Scholar 

  46. Lipowski ZJ, Kiriakos RZ (1971) Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 12:398–401

    Article  CAS  PubMed  Google Scholar 

  47. Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9–19

    Article  PubMed  Google Scholar 

  48. Ma J, Meng N, Xu X, Zhou F, Qu Y (2014) System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 92:e594–e601

    Article  CAS  PubMed  Google Scholar 

  49. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799

    Article  PubMed  Google Scholar 

  50. Matet A, Daruich A, Zola M, Behar-Cohen F (2017) Risk factors for recurrences of central serous chorioretinopathy. Retina. https://doi.org/10.1097/IAE.0000000000001729

    Google Scholar 

  51. Matsumoto H, Kishi S, Otani T, Sato T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162–168

    Article  PubMed  Google Scholar 

  52. Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946

    Article  PubMed  Google Scholar 

  53. Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126

    Article  PubMed  PubMed Central  Google Scholar 

  54. Nicholson BP, Atchison E, Idris AA, Bakri SJ (2017) Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 63(1):1–8. https://doi.org/10.1016/j.survophthal.2017.06.008

    Article  PubMed  Google Scholar 

  55. Nicolò M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153:474–480.e1

    Article  PubMed  Google Scholar 

  56. Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936

    Article  CAS  PubMed  Google Scholar 

  57. O’Keefe JH, Abuissa H, Pitt B (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 10:492–497

    Article  PubMed  Google Scholar 

  58. Peiretti E, Ferrara DC, Caminiti G, Mura M, Hughes J (2015) Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 35:1360–1367

    Article  PubMed  Google Scholar 

  59. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S (2008) Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 28:1008–1012

    Article  PubMed  Google Scholar 

  60. Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study Group (2016) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37(5):1115. https://doi.org/10.1007/s10792-016-0377-2

    Article  Google Scholar 

  61. Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725

    Article  PubMed  Google Scholar 

  62. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators EPHESUS (2008) Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118:1643–1650

    Article  CAS  PubMed  Google Scholar 

  63. Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM (2015) Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 160:581–587.e1

    Article  PubMed  Google Scholar 

  64. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 17:99–103

    PubMed  PubMed Central  Google Scholar 

  65. Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ et al (2017) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina. https://doi.org/10.1097/IAE.0000000000001649

    PubMed  Google Scholar 

  66. Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315.e2

    Article  PubMed  Google Scholar 

  67. Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466

    Article  CAS  PubMed  Google Scholar 

  68. Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R (2000) Subthreshold (RPE) photocoagulation in macular diseases – a pilot study. Br J Ophthalmol 84:40–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011841.pub2

    PubMed  PubMed Central  Google Scholar 

  70. Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555

    Article  PubMed  PubMed Central  Google Scholar 

  71. Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M (2017) Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol 95(7):e610. https://doi.org/10.1111/aos.13491

    Article  CAS  PubMed  Google Scholar 

  73. Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309.e1

    Article  PubMed  Google Scholar 

  74. Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, Bhende P, Bhende M, Shetty NS, Baluswamy S (2004) Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 111:1708–1714

    Article  PubMed  Google Scholar 

  75. Shin MC, Lim JW (2011) Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 31:1937–1943

    Article  CAS  PubMed  Google Scholar 

  76. Shinojima A, Hirose T, Mori R, Kawamura A, Yuzawa M (2010) Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina 30:193–202

    Article  PubMed  Google Scholar 

  77. Shinojima A, Sawa M, Sekiryu T, Oshima Y, Mori R, Hara C, Sugano Y, Kato A, Asato H, Yuzawa M et al (2017) A Multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica 237:159–166. https://doi.org/10.1159/000455807

    Article  CAS  PubMed  Google Scholar 

  78. Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M (2016) Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:15–22

    Article  CAS  PubMed  Google Scholar 

  79. Spaide RF, Klancnik JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825–833

    Article  PubMed  Google Scholar 

  80. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996a) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103(2080):2070–2079

    Article  CAS  PubMed  Google Scholar 

  81. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996b) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16:203–213

    Article  CAS  PubMed  Google Scholar 

  82. Spitznas M (1986) Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 224:321–324

    Article  CAS  PubMed  Google Scholar 

  83. Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, Sen E, Ozdal P, Ozturk F (2014) Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int J Ophthalmol 7:350–354

    PubMed  PubMed Central  Google Scholar 

  84. Tseng CC, Chen SN. (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99(8):1070–1077. https://doi.org/10.1136/bjophthalmol-2014-305353

    Google Scholar 

  85. Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R (2013) Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 251(7):1697–1705. https://doi.org/10.1007/s00417-013-2270-2

    Google Scholar 

  86. Verma L, Sinha R, Venkatesh P, Tewari H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484. BMC Ophthalmol 4:15

    Article  PubMed  PubMed Central  Google Scholar 

  87. Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 238:76–80

    Article  CAS  PubMed  Google Scholar 

  88. Wong R, Chopdar A, Brown M (2004) Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye 18:262–268

    Article  CAS  PubMed  Google Scholar 

  89. Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV (2017) Nondamaging retinal laser theray for treatment of central serous chorioretinopathy: what is the evidence? Retina 37:1021–1033

    Article  PubMed  Google Scholar 

  90. Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386

    Article  CAS  PubMed  Google Scholar 

  91. Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712

    Article  PubMed  Google Scholar 

  92. Yannuzzi LA (1986) Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 84:799–845

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA (1984) Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 91:1554–1572

    Article  CAS  PubMed  Google Scholar 

Download references

Redaktionskomitee

PD Dr. Dr. Clemens Lange, Freiburg (federführend)

PD Dr. Felix Treumer, Kiel

Prof. Dr. Bernd Bertram, Aachen

Prof. Dr. Nicolas Feltgen, Göttingen

Prof. Dr. Hans Hoerauf, Göttingen

Prof. Dr. Daniel Pauleikhoff, Münster

Prof. Dr. Johann Roider, Kiel

Author information

Authors and Affiliations

    Consortia

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)

    Deutsche Ophthalmologische Gesellschaft (DOG)

    Retinologische Gesellschaft e. V. (RG)

    Ethics declarations

    Interessenkonflikt

    Siehe (Tab. 1) im Anhang.

    Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

    Additional information

    Diese Stellungnahme erscheint ebenfalls in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, Georg Thieme Verlag, Stuttgart.

    Die Onlineversion dieses Artikels wurde geändert: leider wurde der Beitrag mit fehlerhafter Abbildung 1 veröffentlicht, auch hat sich im Abschnitt Kernaussagen, Therapie, Lasertherapie ein Fehler eingeschlichen. Zusätzlich wurde der Berufsverband der Augenärzte Deutschlands (BVA) falsch abgekürzt.

    Anhang

    Anhang

    Tab. 1 Tabellarische Zusammenfassung der Erklärungen über Interessenkonflikte. Stellungnahme Chorioretinopathia centralis serosa (CCS)
    Full size table

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)., Deutsche Ophthalmologische Gesellschaft (DOG). & Retinologische Gesellschaft e. V. (RG). Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS). Ophthalmologe 115, 388–399 (2018). https://doi.org/10.1007/s00347-018-0680-6

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00347-018-0680-6

    Search

    Navigation